Hepatotoxicity of chemotherapeutic agents: current state of the problem
- Authors: Vatutin M.T1,2, Sklyannaya E.V1,2, El-Khatib M.A.1,3, Starchenko S.V2, Makarova M.V2
-
Affiliations:
- M. Gorky Donetsk National Medical University
- V.K. Gusak Institute of Emergency and Reconstructive Surgery
- Center for Primary Health Care N5
- Issue: Vol 21, No 6 (2016)
- Pages: 325-333
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40330
- DOI: https://doi.org/10.18821/1028-9984-2016-21-6-325-333
- ID: 40330
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
M. T Vatutin
M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive SurgeryDonetsk, 83003, Ukraine
E. V Sklyannaya
M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive SurgeryDonetsk, 83003, Ukraine
Mariam A. El-Khatib
M. Gorky Donetsk National Medical University; Center for Primary Health Care N5
Email: el-khatib.mariam@yandex.ru
Undergraduate of Department of Hospital Therapy of the M. Gorky Donetsk National Medical University Donetsk, 83003, Ukraine
S. V Starchenko
V.K. Gusak Institute of Emergency and Reconstructive SurgeryDonetsk, 83045, Ukraine;
M. V Makarova
V.K. Gusak Institute of Emergency and Reconstructive SurgeryDonetsk, 83045, Ukraine;
References
- Lewis J.H. Drug-induced liver disease. Med. Clin. N. Am. 2000; 84(5): 1275-311.
- Lee W. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003; 349(5):474-85.
- Larrey D. Drug-induced liver diseases. J. Hepatol. 2000; 32 (1 Suppl.): 77-88.
- Лопаткина Т.Н., Бурневич Э.З. Лекарственные поражения печени. Врач. 2003; (12): 18-20.
- Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment. Pharmacol. Ther. 2006; 23(1):11-25.
- Ishak K.G., Zimmerman H.J. Morphologic spectrums of drug-induced liver disease. Gastroenterol. Clin. N. Am. 1995; 24(4): 759-86.
- Navarro V.J., Senior J.R. Drug - related hepatotoxicity. N. Engl. J. Med. 2006; 354(7): 731-9.
- Faggioli P., De Paschale M., Tocci A., Luoni M., Fava S., De Paoli A. et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica. 1997; 82(1): 38-42.
- Ghabril M., Chalasani N., Björnsson E. Drug-induced liver injury: a clinical update. Curr. Opin. Gastroenterol. 2010; 26(3): 222-6. doi: 10.1097/MOG.0b013e3283383c7c.
- Phillips K.A., Veenstra D.L., Oren E., Lee J. K., Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J. A. M. A. 2001; 286(18): 2270-9.
- Kazuto T., Yukihiro S. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J. Gastroenterol. 2008; 14(44): 6774-85. doi: 10.3748/wjg.14.6774
- Aithal P.G., Day C.P. The natural history of histologically proved drug induced liver disease. Gut. 1999; 44(5): 731-5.
- Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J. Hepatol. 1990; 11(2): 272-6.
- Rodriguez-Frias E.A., Lee W.M. Cancer chemotherapy I: hepatocellular injury. Clin. Liver Dis. 2007; 11(3): 641-62.
- Lee W. Drug-induced hepatotoxicity. N. Engl. J. Med. 1995; 333(17): 1118-27.
- Курмуков И.А. Лекарственное поражение печени при лечении онкогематологических заболеваний. Клиническая онкогематология. 2010; (1): 60-7.
- Голованова Е.В. Возможности патогенетической терапии при лекарственных поражениях печени. Эффективная фармакотерапия. 2011; (3): 60-4.
- Torrisi J.M., Schwartz L.H., Gollub M.J., Ginsberg M.S., Bosl G.J., Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011; 258(1): 41-56. doi: 10.1148/radiol.10092129.
- Markowitz J.S., Donovan J.L., DeVane C.L. Taylor R.M., Ruan Y., Wang J.S. et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P4503A4 enzyme. J. A. M. A. 2003; 290(11): 1500-4.
- Ding X., Kaminsky L.S. Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003; 43: 149-73.
- Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346(16): 1221-31.
- van der Bol J.M., Mathijssen R.H., Loos W.J., Friberg L.E., van Schaik R.H., de Jonge M.J. et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol. 2007; 25(19): 2719-26.
- Field K.M., Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol. 2008; 9(12): 1181-90. doi: 10.1016/S1470-2045(08)70307-3.
- Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. 2002; 22(2): 137-44.
- Floyd J., Mirza I., Sachs B., Perry M.C. Hepatotoxicity of chemotherapy. Semin. Oncol. 2006; 33(1): 50-67.
- King P.D., Perry M.C. Hepatotoxicity of chemotherapy. Oncologist. 2001; 6(2): 162-76.
- Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug. Saf. 2006; 15(4): 241-3.
- Галимова С.Ф. Лекарственные поражения печени (часть I). Здравоохранение (Минск). 2013; (7): 41-50.
- Казюлин А.Н., Вельшер Л.З., Королева И.А. Возможности преодоления гепатотоксичности при проведении комбинированного и комплексного лечения рака молочной железы. Эффективная фармакотерапия. 2011; (3): 66-72.
- Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J. et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am. J. Gastroenterol. 2014; 109(7): 950-66. doi: 10.1038/ajg.2014.131.
- Norris W., Paredes A.H., Lewis J.H. Drug-induced liver injury in 2007. Curr. Opin. Gastroenterol. 2008; 24(3): 287-97. doi: 10.1097/MOG.0b013e3282f9764b.
- Lee W.M., Senior J.R. Recognizing drug induced liver injury: current problems, possible solutions. Toxicol. Pathol. 2005; 33: 155-64.
- Hoofnagle J.H. Drug-Induced Liver Injury Network (DILIN). Hepatology. 2004; 40(4):773.
- Ивашкин В.Т., Буеверов А.О. Патогенетическое и клиническое обоснование применения адеметионина в лечении больных с внутрипеченочным холестазом. Клинические перспективы гастроэнтерологии, гепатологии. 2009; (5): 24-9.
- Petrovic V., Teng S., Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol. Interv. 2007; 7(2): 99-111.